tirzepatide being discontinued A Major GLP-1 Drug Shortage Is Over. Some Patients Aren't Celebrating Stopping Tirzepatide Leads to Rebound

Discussion An emerging literature indicates that activating central GLP-1Rs is sufficient to reduce cocaine-seeking behavior 8,14,18 , findings that support translational studies focused on re-purposing GLP-1R agonists to treat CUD 5,22

Additionally, the cost of these medications can be a factor for long-term use

and the EU (Grant agreement 101100859 and 101158172) (N.L.)

While clinical trials conducted in Croatia in the early 2000s determined BPC 157 to be safe and effective in humans for the treatment of inflammatory bowel disease, there appears to be a lack of trials conducted in the U.S

So, when the FDA announced the tirzepatide drug shortage was over, a group of compounded pharmacies contested the decision, insisting that it wasnt